Taeniasis is an illness which is shared between humans and animals. Our dedicated research and development services in taeniasis are designed to push the boundaries of scientific innovation. With our integrated approach, we strive to offer pharmaceutical companies worldwide expert solutions.
Overview of Taeniasis
Tapeworms from the Taenia genus such as Taenia saginata known as beef tapeworms and Taenia solium known as pork tapeworms, are the main cause of taeniasis, which is a parasitic infection. Taeniasis is contracted when contaminated or undercooked meat containing larval cysticerci of these parasites is eaten. Furthermore, an individual can also acquire T. solium taeniasis through fecal-oral means by ingesting eggs which could further escalate to neurocysticercosis as more of a severe condition.
Fig.1 Taenia spp. egg found in human feces. (Symeonidou, I., et al., 2018)
Vaccine Development for Taeniasis
Porcine Vaccines
Major progress has already been made in the quest to develop a vaccine for porcine cysticercosis which is a closely related disease to taeniasis. Two leading vaccine candidates, SP3VAC and TSOL18, have demonstrated high protection levels in pigs against both experimental and natural challenges to Taenia solium infection.
Bovine Vaccines
Also there has been research done towards vaccinating against Taenia saginata in cattle. It was shown that the vaccine TSA9/TSA18 is highly efficacious against Taenia Saginata cysticercosis in cattle. But because of insufficient commercial interest, this vaccine is not being developed presently.
Therapeutics Development for Taeniasis
The pillar of taeniasis therapeutic is focused on the use of anthelmintic medications which function against the adult forms of Taenia. Some of the most commonly used drugs include:
- Praziquantel: This drug is considered first line therapeutic and has displayed high efficacy (95%) in treating taeniasis.
- Niclosamide: Another therapeutic with efficacy of 85%.
- Albendazole: This drug is capable of curing all Taenia spp. cases when administered in a triple dose regimen, thus has shown an efficacy of 100%.
Our Services
Our services encompass all aspects of vaccine development which include antigen selection and preclinical testing. With the most up to date technologies, our talented staff is able to construct effective and safe vaccines.
In addition, we improve existing anthelmintic medicines by studying, creating, and analyzing new ones. Our therapeutic development services are geared towards increasing effectiveness while reducing side effects of the current therapeutics.
Disease Models
- Taenia solium Infection Pig Models
- Taenia saginata Infection Cattle Models
- Taenia asiatica Infection Gerbils Models
Other species: Mice, Rats, Voles, Hamsters, Dogs, or Monkeys
The development of vaccines and therapeutics for taeniasis is a complex process that requires a deep understanding of the disease, its causative agents, and the host-parasite interactions. Our company is committed to advancing the science of taeniasis control through innovative research and development services. If you are interested in our services, please feel free to contact us.
References
- Okello, Anna L., and Lian Francesca Thomas. "Human taeniasis: current insights into prevention and management strategies in endemic countries." Risk Management and Healthcare Policy (2017): 107-116.
- Symeonidou, Isaia, et al. "Human taeniasis/cysticercosis: a potentially emerging parasitic disease in Europe." Annals of gastroenterology 31.4 (2018): 406.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
